PT2607484E - Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne - Google Patents

Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne Download PDF

Info

Publication number
PT2607484E
PT2607484E PT131603383T PT13160338T PT2607484E PT 2607484 E PT2607484 E PT 2607484E PT 131603383 T PT131603383 T PT 131603383T PT 13160338 T PT13160338 T PT 13160338T PT 2607484 E PT2607484 E PT 2607484E
Authority
PT
Portugal
Prior art keywords
exon
mrna
methods
muscular dystrophy
duchenne muscular
Prior art date
Application number
PT131603383T
Other languages
English (en)
Inventor
Boudewijn Van Ommen Garrit-Jan
Johannes Platenburg Gerardus
Johannes De Kimpe Josephus
Christina Theodora Van Deutekom Judith
Aartsma-Rus Annemieke
Original Assignee
Academisch Ziekenhuis Leiden
Biomarin Tech Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40873329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2607484(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/NL2008/050673 external-priority patent/WO2009054725A2/en
Application filed by Academisch Ziekenhuis Leiden, Biomarin Tech Bv filed Critical Academisch Ziekenhuis Leiden
Publication of PT2607484E publication Critical patent/PT2607484E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT131603383T 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne PT2607484E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2008/050673 WO2009054725A2 (en) 2007-10-26 2008-10-27 Means and methods for counteracting muscle disorders

Publications (1)

Publication Number Publication Date
PT2607484E true PT2607484E (pt) 2016-03-09

Family

ID=40873329

Family Applications (2)

Application Number Title Priority Date Filing Date
PT131603383T PT2607484E (pt) 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
PT09788160T PT2344637E (pt) 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT09788160T PT2344637E (pt) 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne

Country Status (15)

Country Link
EP (4) EP2344637B2 (pt)
JP (2) JP5786109B2 (pt)
AU (1) AU2009310557B2 (pt)
CA (3) CA2741629C (pt)
CY (1) CY1116305T1 (pt)
DK (2) DK2344637T4 (pt)
ES (2) ES2532634T5 (pt)
HK (1) HK1160169A1 (pt)
HR (1) HRP20160078T1 (pt)
IL (2) IL212508A (pt)
NZ (1) NZ592498A (pt)
PL (1) PL2607484T3 (pt)
PT (2) PT2607484E (pt)
SI (1) SI2607484T1 (pt)
WO (2) WO2010050801A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228711A1 (en) 2004-06-28 2017-10-11 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
PT2203173E (pt) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Resumo
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN105779453A (zh) 2008-10-24 2016-07-20 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
US8802437B2 (en) * 2009-09-24 2014-08-12 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
JP5963678B2 (ja) 2009-11-12 2016-08-03 ジ ユニバーシティ オブ ウェスタン オーストラリア 病状を治療するためのアンチセンス分子及び方法
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP2014507143A (ja) * 2011-02-08 2014-03-27 ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング/ビジネス/アズ キャロライナズ ヘルスケア システム アンチセンスオリゴヌクレオチド
WO2013100190A1 (ja) 2011-12-28 2013-07-04 日本新薬株式会社 アンチセンス核酸
CA3120918A1 (en) * 2012-01-27 2013-08-01 Biomarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
BR112014033004B1 (pt) * 2012-07-03 2021-10-19 Biomarin Technologies B.V. Oligonucleotídeo para tratamento de pacientes com distrofia muscular
JP6449231B2 (ja) 2013-03-14 2019-01-09 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
MX2015013117A (es) 2013-03-15 2016-07-14 Sarepta Therapeutics Inc Composiciones mejoradas para tratar distrofia muscular.
WO2015035231A1 (en) * 2013-09-05 2015-03-12 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
JP6519842B2 (ja) * 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
TR201901939T4 (tr) 2014-03-12 2019-03-21 Nat Center Neurology & Psychiatry Antisens nükleik asit.
US10308940B2 (en) 2014-06-10 2019-06-04 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of Pompe disease
EP3778895A1 (en) 2015-09-15 2021-02-17 Nippon Shinyaku Co., Ltd. Antisense nucleic acid
KR20180056766A (ko) 2015-10-09 2018-05-29 웨이브 라이프 사이언시스 리미티드 뉴클레오티드 조성물 및 이의 방법
CN108778344A (zh) * 2016-03-02 2018-11-09 里兰斯坦福初级大学理事会 抗流感病毒的泛基因型药剂和其使用方法
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
EP3445405A4 (en) 2016-04-18 2019-12-18 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERS AND METHOD FOR USE THEREOF TO TREAT DISEASES RELATING TO THE ACID ALPHA GLUCOSIDASE GENE
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
CN109311919A (zh) 2016-06-30 2019-02-05 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体
IL301091A (en) * 2016-07-05 2023-05-01 Biomarin Tech Bv Oligonucleotides containing a bicyclic skeleton and their use for the treatment of genetic diseases
CN110290812B (zh) 2016-12-19 2023-06-02 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
DK3554552T3 (da) 2016-12-19 2022-10-24 Sarepta Therapeutics Inc Exon-skipping-oligomerkonjugater mod muskeldystrofi
DK4122497T3 (da) 2016-12-19 2024-06-10 Sarepta Therapeutics Inc Exonskipping-oligomerkonjugater til muskeldystrofi
SG10202107429WA (en) 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
GB201711809D0 (en) * 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
JP2020536058A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法
MX2020003596A (es) 2017-10-04 2020-07-22 Avidity Biosciences Inc Composiciones de acido nucleico-polipeptido y usos de las mismos.
CA3083526A1 (en) 2017-12-06 2019-06-13 Andrew John Geall Compositions and methods of treating muscle atrophy and myotonic dystrophy
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US20220251551A1 (en) * 2018-06-13 2022-08-11 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20210081322A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN113383078A (zh) * 2018-12-06 2021-09-10 波涛生命科学有限公司 寡核苷酸组合物及其方法
AU2020287880A1 (en) 2019-06-06 2022-01-20 Avidity Biosciences, Inc. UNA amidites and uses thereof
EP3980436A4 (en) 2019-06-06 2023-12-20 Avidity Biosciences, Inc. NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
IL293997A (en) * 2019-12-19 2022-08-01 Nippon Shinyaku Co Ltd Antistrand nucleic acids that allow exon skipping
MX2022007937A (es) 2019-12-26 2022-07-27 Nippon Shinyaku Co Ltd Acido nucleico antisentido que induce la omision del exon 50.
IL295967A (en) 2020-02-28 2022-10-01 Nippon Shinyaku Co Ltd Antisense nucleic acids for splicing on exon 51
JP2023537798A (ja) 2020-03-19 2023-09-06 アビディティー バイオサイエンシーズ,インク. 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386239A1 (en) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US6727355B2 (en) * 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP3228711A1 (en) * 2004-06-28 2017-10-11 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
JP2008538500A (ja) * 2005-04-22 2008-10-30 アカデミス ツィーケンホイス ライデン SRタンパク質の結合に対する干渉とRNA二次構造に対する干渉による、mRNA前駆体におけるエクソン認識の調節
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
PT2203173E (pt) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Resumo
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN105779453A (zh) * 2008-10-24 2016-07-20 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
US9607308B2 (en) 2011-06-29 2017-03-28 American Express Travel Related Services Company, Inc. Spend based digital ad targeting and measurement

Also Published As

Publication number Publication date
JP2012506697A (ja) 2012-03-22
EP2607484A1 (en) 2013-06-26
PT2344637E (pt) 2015-03-23
CA2741793C (en) 2018-10-30
WO2010050802A3 (en) 2010-08-12
AU2009310557A8 (en) 2011-09-29
EP2344637A1 (en) 2011-07-20
EP3400948A1 (en) 2018-11-14
AU2009310557B2 (en) 2014-09-11
EP2349287B1 (en) 2018-08-15
DK2607484T3 (en) 2016-03-07
NZ592498A (en) 2012-05-25
WO2010050801A1 (en) 2010-05-06
CA2741629A1 (en) 2010-05-06
CY1116305T1 (el) 2017-02-08
AU2009310557A1 (en) 2010-05-06
EP2607484B1 (en) 2016-01-06
ES2532634T5 (es) 2018-04-30
CA2741629C (en) 2022-07-05
EP3400948B1 (en) 2022-11-02
HRP20160078T1 (hr) 2016-04-08
IL212508A0 (en) 2011-06-30
JP5905260B2 (ja) 2016-04-20
WO2010050802A2 (en) 2010-05-06
AU2009310558A8 (en) 2015-01-22
DK2344637T4 (en) 2018-04-23
IL212509A0 (en) 2011-06-30
ES2532634T3 (es) 2015-03-30
PL2607484T3 (pl) 2016-06-30
JP2012506698A (ja) 2012-03-22
EP2349287A2 (en) 2011-08-03
SI2607484T1 (sl) 2016-11-30
IL212508A (en) 2013-11-28
JP5786109B2 (ja) 2015-09-30
ES2562658T3 (es) 2016-03-07
IL212509A (en) 2016-04-21
AU2009310558B2 (en) 2014-09-04
CA3017539A1 (en) 2010-05-06
AU2009310558A1 (en) 2010-05-06
HK1160169A1 (en) 2012-08-10
CA2741793A1 (en) 2010-05-06
EP2344637B1 (en) 2014-12-24
DK2344637T3 (en) 2015-02-02
EP2344637B2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
IL212508A0 (en) Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
IL282772A (en) Methods for efficient deletion of exon 44 in patients and means involved in this
HK1185098A1 (zh) 高效跳過裘馨氏肌肉營養不良症前體 外顯子 的方法和工具
IL278833A (en) Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
EP2296805A4 (en) PROCESS AND APPARATUS FOR THE MANUFACTURE OF TITANIUM ALUMINUM ALLOYS
ZA201100651B (en) Method for dispersing and separating nanotubes
EP2247950A4 (en) METHODS AND COMPOSITIONS FOR DETECTING MICROORGANISMS
GB0818401D0 (en) Fastener feed method and apparatus
PL2388085T3 (pl) Urządzenie do mieszania i sposób topienia
HK1160721A1 (en) Methods and apparatuses for plant aeration
HK1132307A1 (en) Electroplating device and method for electroplating
EP2190986A4 (en) HYBRIDIZATION METHOD AND APPARATUS
EP2340315A4 (en) COMPOSITIONS AND METHODS FOR DETECTION OF JAK2 NUCLEIC ACID MUTATIONS
GB0823333D0 (en) Apparatus and methods
IL209324A0 (en) Aliskiren monofumarate and processes for preparation thereof
EP2495040A4 (en) AGITATOR DEVICE AND STIRRER HOOKS FOR THE SAME
EP2319247A4 (en) METHODS AND APPARATUS FOR PROCESSING AND DISPLAYING IMAGE
GB0823408D0 (en) Apparatus and methods
EP2330950A4 (en) LOCKABLE LOCHWORK MOUNTING AND METHOD
TWI368845B (en) Multimedia palying method and apparatus thereof
TWI371971B (en) De-interlacing method and apparatus
TWI347126B (en) Dynamic de-interlacing method and apparatus
GB0713944D0 (en) In-Vessel composting apparatus and method